

Trastuzumab deruxtecan DESTINY-Breast03

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



#### Serious and disabling adverse effects



#### Other adjustments




Early stopping or crossover also long-term plateau in the PFS curve



Trastuzumab deruxtecan DESTINY-Breast03

### FINAL SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Therapeutic Indication: Treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti HER2 based regimens

Experimental Arm: Trastuzumab deruxtecan

Control Arm: Trastuzumab emtansine (T-DM1)



